A river model to map convergent cancer evolution and guide therapy in RCC

Nature Reviews Urology

Volumn 12, Issue 12, 2015, Pages 706-712

  Wei, Elizabeth Y ^a   Hsieh, James J ^b  

^a Human Oncology and Pathogenesis Program   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR; VON HIPPEL LINDAU PROTEIN; TUMOR MARKER;

BREAST CANCER; CANCER GROWTH; CANCER MORPHOLOGY; CANCER PROGNOSIS; CANCER RESISTANCE; CARCINOGENESIS; CELL HETEROGENEITY; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; CONVERGENT EVOLUTION; DISEASE COURSE; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC MODEL; GENETIC VARIABILITY; GENOMICS; HETEROZYGOSITY LOSS; HUMAN; INTRATUMORAL HETEROGENEITY; KIDNEY CARCINOMA; METASTASIS POTENTIAL; MOLECULARLY TARGETED THERAPY; MULTIPLE MYELOMA; PRIORITY JOURNAL; REVIEW; SEQUENCE ANALYSIS; ANIMAL; CARCINOMA, RENAL CELL; KIDNEY NEOPLASMS; METABOLISM; PATHOLOGY; RIVER;

ANIMALS; BIOMARKERS, TUMOR; CARCINOGENESIS; CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; RIVERS;

EID: 84949625431     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2015.260     Document Type: Review

References (69)

1. Druker, B. J. et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031-1037 (2001).
2. Heinrich, M. C. et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 21, 4342-4349 (2003).
3. Leemans, C. R., Braakhuis, B. J. & Brakenhoff, R. H. The molecular biology of head and neck cancer. Nat. Rev. Cancer 11, 9-22 (2011).
4. Brockstein, B. E. & Vokes, E. E. Head and neck cancer in 2010: Maximizing survival and minimizing toxicity. Nat. Rev. Clin. Oncol. 8, 72-74 (2011).
5. Kris, M. G. et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290, 2149-2158 (2003).
6. Kwak, E. L. et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363, 1693-1703 (2010).
7. Flaherty, K. T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809-819 (2010).
8. Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516 (2011).
9. Cobleigh, M. A. et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17, 2639-2648 (1999).
10. Vogel, C. L. et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20, 719-726 (2002).
11. Hudes, G. et al. Temsirolimus, interferon α, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356, 2271-2281 (2007).
12. Motzer, R. J. et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N. Engl. J. Med. 369, 722-731 (2013).
13. Ko, J. J. et al. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. Lancet Oncol. 16, 293-300 (2015).
14. Bhatt, J. R. & Finelli, A. Landmarks in the diagnosis and treatment of renal cell carcinoma. Nat. Rev. Urol. 11, 517-525 (2014).
15. Motzer, R. J. et al. Sunitinib versus interferon α in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115-124 (2007).
16. Motzer, R. J. et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24, 16-24 (2006).
17. National Comprehensive Cancer Network®. NCCN categories of evidence and consensus [online], http://www.nccn.org/professionals/physician-gls/categories-of-consensus.asp (2015).
18. National Comprehensive Cancer Network®. Kidney Cancer Version 3.2015 [online], http://www.nccn.org/professionals/physician-gls/pdf/kidney.pdf (2015).
19. Cooke, S. L. et al. Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma. Oncogene 29, 4905-4913 (2010).
20. Li, X. et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J. Natl Cancer Inst. 100, 672-679 (2008).
21. Hiley, C., de Bruin, E. C., McGranahan, N. & Swanton, C. Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine. Genome Biol. 15, 453 (2014).
22. Shah, N. P. & Sawyers, C. L. Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene 22, 7389-7395 (2003).
23. Gerstung, M. et al. Reliable detection of subclonal single-nucleotide variants in tumour cell populations. Nat. Commun. 3, 811 (2012).
24. Yap, T. A., Gerlinger, M., Futreal, P. A., Pusztai, L. & Swanton, C. Intratumor heterogeneity: seeing the wood for the trees. Sci. Transl. Med. 4, 127ps10 (2012).
25. Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883-892 (2012).
26. Jiang, F. et al. Construction of evolutionary tree models for renal cell carcinoma from comparative genomic hybridization data. Cancer Res. 60, 6503-6509 (2000).
27. Martinez, P. et al. Parallel evolution of tumour subclones mimics diversity between tumours. J. Pathol. 230, 356-364 (2013).
28. Gerlinger, M. et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat. Genet. 46, 225-233 (2014).
29. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499, 43-49 (2013).
30. Swanton, C. Intratumor heterogeneity: evolution through space and time. Cancer Res. 72, 4875-4882 (2012).
31. Hakimi, A. A., Pham, C. G. & Hsieh, J. J. A clear picture of renal cell carcinoma. Nat. Genet. 45, 849-850 (2013).
32. Brugarolas, J. Molecular genetics of clear-cell renal cell carcinoma. J. Clin. Oncol. 32, 1968-1976 (2014).
33. Hakimi, A. A. et al. Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. Eur. Urol. 63, 848-854 (2013).
34. Hakimi, A. A. et al. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA Research Network. Clin. Cancer Res. 19, 3259-3267 (2013).
35. Fisher, R., Pusztai, L. & Swanton, C. Cancer heterogeneity: implications for targeted therapeutics. Br. J. Cancer 108, 479-485 (2013).
36. Merlo, L. M., Pepper, J. W., Reid, B. J. & Maley, C. C. Cancer as an evolutionary and ecological process. Nat. Rev. Cancer 6, 924-935 (2006).
37. Carter, S. L., Eklund, A. C., Kohane, I. S., Harris, L. N. & Szallasi, Z. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat. Genet. 38, 1043-1048 (2006).
38. Zhang, J. et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science 346, 256-259 (2014).
39. Gillies, R. J., Verduzco, D. & Gatenby, R. A. Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nat. Rev. Cancer 12, 487-493 (2012).
40. Su, K.-Y. et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J. Clin. Oncol. 30, 433-440 (2012).
41. Inukai, M. et al. Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res. 66, 7854-7858 (2006).
42. Roche-Lestienne, C. et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 100, 1014-1018 (2002).
43. Shah, N. P. et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2, 117-125 (2002).
44. Sankin, A. et al. The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling. Cancer Med. 3, 1485-1492 (2014).
45. Shen, C. & Kaelin, W. G. Jr. The VHL/HIF axis in clear cell renal carcinoma. Semin. Cancer Biol. 23, 18-25 (2013).
46. Voss, M. H., Hsieh, J. J. & Motzer, R. J. Novel approaches targeting the vascular endothelial growth factor axis in renal cell carcinoma. Cancer J. 19, 299-306 (2013).
47. Albiges, L. et al. Complete remission with tyrosine kinase inhibitors in renal cell carcinoma. J. Clin. Oncol. 30, 482-487 (2012).
48. Gerlinger, M. & Swanton, C. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Br. J. Cancer 103, 1139-1143 (2010).
49. Katayama, R. et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci. Transl. Med. 4, 120ra17 (2012).
50. Voss, M. H. et al. Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy. Clin. Cancer Res. 20, 1955-1964 (2014).
51. Cheng, D. T. et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J. Mol. Diagn. 17, 251-264 (2015).
52. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011).
53. Linehan, W. M., Srinivasan, R. & Schmidt, L. S. The genetic basis of kidney cancer: a metabolic disease. Nat. Rev. Urol. 7, 277-285 (2010).
54. Fidler, I. J. & Poste, G. The "seed and soil" hypothesis revisited. Lancet Oncol. 9, 808 (2008).
55. Campbell, P. J. et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467, 1109-1113 (2010).
56. Torres, L. et al. Intratumor genomic heterogeneity in breast cancer with clonal divergence between primary carcinomas and lymph node metastases. Breast Cancer Res. Treat. 102, 143-155 (2007).
57. Marusyk, A., Almendro, V. & Polyak, K. Intra-tumour heterogeneity: a looking glass for cancer? Nat. Rev. Cancer 12, 323-334 (2012).
58. Canfield, K. et al. Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells. Cell Cycle 14, 648-655 (2015).
59. Tvorogov, D. et al. Somatic mutations of ErbB4: selective loss-of-function phenotype affecting signal transduction pathways in cancer. J. Biol. Chem. 284, 5582-5591 (2009).
60. Williams, C. S. et al. ERBB4 is over-expressed in human colon cancer and enhances cellular transformation. Carcinogenesis 36, 710-718 (2015).
61. Iwasa, Y., Nowak, M. A. & Michor, F. Evolution of resistance during clonal expansion. Genetics 172, 2557-2566 (2006).
62. rd edn (eds Bukowski, R., Figlin, R. A. & Motzer, R.) 111-151 (Springer, 2015).
63. Juric, D. et al. Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor. Nature 518, 240-244 (2015).
64. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01219699 (2014).
65. Ojha, J. et al. Deep sequencing identifies genetic heterogeneity and recurrent convergent evolution in chronic lymphocytic leukemia. Blood 125, 492-498 (2015).
66. Melchor, L. et al. Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma. Leukemia 28, 1705-1715 (2014).
67. Misale, S., Di Nicolantonio, F., Sartore-Bianchi, A., Siena, S. & Bardelli, A. Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. Cancer Discov. 4, 1269-1280 (2014).
68. Gatenby, R. A. & Gillies, R. J. A microenvironmental model of carcinogenesis. Nat. Rev. Cancer 8, 56-61 (2008).
69. Gatenby, R. A., Gillies, R. J. & Brown, J. S. Of cancer and cave fish. Nat. Rev. Cancer 11, 237-238 (2011).